Article
Biochemistry & Molecular Biology
Anastasios Gkountakos, Giovanni Centonze, Emanuele Vita, Lorenzo Belluomini, Michele Milella, Emilio Bria, Massimo Milione, Aldo Scarpa, Michele Simbolo
Summary: The use of EGFR tyrosine kinase inhibitors has significantly improved the management of lung adenocarcinoma, but long-term clinical benefit is compromised by multiple resistance mechanisms, including metabolic remodeling. Metabolic pathways and metabolites have been implicated in resistance to EGFR TKIs and they may also serve as predictive biomarkers. Additionally, targeting nutrient dependencies may offer a potential strategy to counteract resistance.
Article
Medicine, General & Internal
Yuman Yu, Yuehong Wang, Linying Wu, Xuanli Xu, Hua Zhou, Qing Wang, Jianying Zhou
Summary: The study evaluated the efficacy of EGFR-TKIs plus bevacizumab in advanced non-squamous EGFR-mutated NSCLC patients with gradual progression, showing that the treatment was well-tolerated and promising. Patients with high baseline serum VEGF levels had better PFS2 than those with low baseline levels.
Article
Oncology
Jeng-Sen Tseng, Kuo-Hsuan Hsu, Zhe-Rong Zheng, Tsung-Ying Yang, Kun-Chieh Chen, Yen-Hsiang Huang, Kang-Yi Su, Sung-Liang Yu, Gee-Chen Chang
Summary: This study found that primary tumor resection (PTR) in advanced lung adenocarcinoma patients treated with EGFR-TKI can lead to significantly better clinical outcomes, including longer progression-free survival and overall survival. Further research is needed to evaluate the biological role of PTR in these patients.
Article
Biotechnology & Applied Microbiology
Jiadi Gan, Yihua Huang, Jun Liao, Lanlan Pang, Wenfeng Fang
Summary: In this study, HER2 amplification was found in 7% of cases with acquired resistance to EGFR-TKIs. Patients with concomitant EGFR mutation and HER2 amplification may benefit from therapies targeting both EGFR and HER2.
ONCOTARGETS AND THERAPY
(2021)
Article
Chemistry, Medicinal
Hui Deng, Qian Lei, Weidong Shang, Ying Li, Liyun Bi, Na Yang, Zhiyi Yu, Weimin Li
Summary: This study describes the design, synthesis, and application of clickable probes for visualizing EGFR activity in cancer cells and tissues. The probes showed high reactivity and selectivity for EGFR kinase, allowing for the discrimination of EGFR mutations and prediction of EGFR-TKI therapy response.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Article
Oncology
Yu-Ra Choi, Eun Hye Kang, Sunshin Kim, Seog-Yun Park, Ji-Youn Han, Youngjoo Lee
Summary: This study evaluated the efficacy of single MET inhibition in EGFR-mutant and MET-amplified lung cancer and found that it produced a short-lived response. Further research on novel combination therapy schedules is needed to achieve long-lasting efficacy with less toxicity.
BRITISH JOURNAL OF CANCER
(2023)
Article
Biotechnology & Applied Microbiology
Cheng-Yu Chang, Yi-Chun Lai, Yu-Feng Wei, Chung-Yu Chen, Shih-Chieh Chang
Summary: Epidermal growth factor receptor (EGFR) mutations are most common in Eastern Asia and EGFR-tyrosine kinase inhibitors (TKIs) are recommended as first-line therapeutic options for non-small cell lung cancer (NSCLC) with sensitizing EGFR mutations. The expression of programmed cell death-ligand 1 (PD-L1) in patients with metastatic NSCLC and EGFR mutations is not uncommon, but its influence on clinical outcomes with standard initial treatment seems to be insignificant.
ONCOTARGETS AND THERAPY
(2021)
Article
Oncology
Kai-Ling Lee, Tsung-Ching Lai, Wei-Jiunn Lee, Yu-Chieh Chen, Kuo-Hao Ho, Wen-Yueh Hung, Yi-Chieh Yang, Ming-Hsien Chan, Feng-Koo Hsieh, Chi-Li Chung, Jer-Hwa Chang, Ming-Hsien Chien
Summary: Non-small-cell lung cancer (NSCLC) is a typical inflammation-associated cancer, and epidermal growth factor (EGF) receptor (EGFR) mutations are the most common driver mutations of NSCLC. This study aimed to evaluate the effects of interleukin (IL)-17A, a proinflammatory cytokine, on EGFR-mediated progression of NSCLC. The results showed that the IL-17A/IL-17RC axis promoted proliferation and resistance to EGFR-tyrosine kinase inhibitors (TKIs) in NSCLC cells with mutant EGFR, and enhanced EGF-induced EGFR activation and cell proliferation in NSCLC cells with wild-type (WT) EGFR by impairing EGFR lysosomal degradation. Developing therapeutic strategies against IL-17A/IL-17RC could be valuable for NSCLC treatment.
Article
Oncology
Min Yu, Xiaoyu Li, Xueqian Wu, Weiya Wang, Yanying Li, Yan Zhang, Shuang Zhang, Yongsheng Wang
Summary: EGFR-TKI treatment can lead to menstrual abnormalities and abnormal vaginal bleeding in premenopausal female NSCLC patients, which may be associated with decreased progesterone level, reduced EGFR activation, and tissue factor (TF) expression in endometrial tissues.
FRONTIERS IN ONCOLOGY
(2022)
Article
Immunology
Zhi Wang, Lingling Zhang, Wenwen Xu, Jie Li, Yi Liu, Xiaozhu Zeng, Maoxi Zhong, Yuxi Zhu
Summary: In this study, we identified potential genes associated with EGFR-TKI resistance in lung cancer and found that SPP1 may play a crucial role in resistance to EGFR-TKIs. Furthermore, high expression of SPP1 was also associated with tumor immune infiltration and poor prognosis.
JOURNAL OF INFLAMMATION RESEARCH
(2022)
Article
Oncology
Mengkai Yang, Tao Zhang, Yangfeng Zhang, Xiaojun Ma, Jing Han, Ke Zeng, Yafei Jiang, Zongyi Wang, Zhuoying Wang, Jing Xu, Yingqi Hua, Zhengdong Cai, Wei Sun
Summary: The study revealed that MYLK4 promotes the growth and metastasis of osteosarcoma by activating the EGFR signaling pathway. Additionally, the combination of MYLK4 and EGFR inhibitors showed synergistic effects on the growth and metastasis of OS in vitro and in vivo.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Pharmacology & Pharmacy
Yaoshuai Zhang, Yongping Li, Yuehua Han, Min Li, Xian Li, Fangtian Fan, Hao Liu, Shanshan Li
Summary: This study explores the potential therapeutic effects of aumolertinib combined with ionizing radiation (IR) in treating brain metastases (BM) tumors from epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC). The results show that the combination enhances the therapeutic effects, inhibits cell proliferation and survival, delays DNA damage repair, increases cell apoptosis rates, and abrogates IR-induced G2/M phase arrest. The clinical study confirms better patient benefits from the combination treatment for EGFR-mutant NSCLC BM patients.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2023)
Article
Oncology
Balazs Gieszer, Zsolt Megyesfalvi, Viktoria Dulai, Judit Papay, Ilona Kovalszky, Jozsef Timar, Janos Fillinger, Tunde Harko, Orsolya Pipek, Vanda Teglasi, Eszter Regos, Gergo Papp, Zoltan Szallasi, Viktoria Laszlo, Ferenc Renyi-Vamos, Gabriella Galffy, Csaba Bodor, Balazs Dome, Judit Moldvay
Summary: This study suggests that high EGFR-aVAF in tumoral tissue predicts benefit from EGFR-TKI treatment in advanced LADC, and that exon 19 EGFR mutation is associated with high EGFR-aVAF and improved survival outcomes.
TRANSLATIONAL LUNG CANCER RESEARCH
(2021)
Review
Pharmacology & Pharmacy
Michael Gekle, Virginie Dubourg, Gerald Schwerdt, Ralf A. Benndorf, Barbara Schreier
Summary: EGFR plays a critical role in the regulation of vascular function and pathogenesis of cardiovascular diseases through the interplay with AT1R.
BIOCHEMICAL PHARMACOLOGY
(2023)
Article
Oncology
Hai Song, Yanpei Wang, Chaojia Shi, Jianxiang Lu, Tian Yuan, Xiangpeng Wang
Summary: This study reveals that SH3KBP1 is highly expressed in GBM and associated with worse survival outcomes, potentially serving as a marker for GSCs. Silencing SH3KBP1 can significantly impair GBM cell proliferation, migration, and GSCs self-renewal, likely acting as an adaptor protein for EGFR signaling.
FRONTIERS IN ONCOLOGY
(2021)